Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease
Data expands mechanistic and translational evidence for selective in vivo programming of monocytes and macrophages, potent peripheral B-cell depletion, and a differentiated cytokine profile CAMBRIDGE, Mass.–(BUSINESS WIRE)–Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, today announced new pre-clinical data supporting LIB820, the company’s lead in vivo … [Read more…]
